Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection

被引:76
作者
Chambers, TJ
Fan, XF
Droll, DA
Hembrador, E
Slater, T
Nickells, MW
Dustin, LB
DiBisceglie, AM
机构
[1] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA
[2] St Louis Univ, Hlth Sci Ctr, Dept Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA
[3] Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA
关键词
D O I
10.1128/JVI.79.5.3071-3083.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution. All patients were treatment naive and had chronic inflammation and fibrosis on biopsy. As part of an analysis of pretreatment variables that might affect the outcome of treatment, genetic heterogeneity within the viral E1-E2 glycoprotein region (nucleotides 851 to 2280) was assessed by sequencing 10 to 15 quasispecies clones per patient from serum-derived PCR products. Genetic parameters were examined with respect to response to therapy based on serum viral RNA loads at 12 weeks (early viral response) and at 24 weeks posttreatment (sustained viral response). Nucleotide and amino acid quasispecies complexities of the hypervariable region 1 (HVR-1) were less in the responder group in comparison to the nonresponder group at 12 weeks, and genetic diversity was also less both within and outside of the HVR-1, with the difference being most pronounced for the non-HVR-1 region of E2. However, these genetic parameters did not distinguish responders from nonresponders for sustained viral responses. Follow-up studies of genetic heterogeneity based on the HVR-1 in selected responders and nonresponders while on therapy revealed greater evolutionary drift in the responder subgroup. The pretreatment population sequences for the NS5A interferon sensitivity determinant region were also analyzed for all patients, but no correlations were found between treatment response and any distinct genetic markers. These findings support previous studies indicating a high level of genetic heterogeneity among chronically infected HCV patients. One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity.
引用
收藏
页码:3071 / 3083
页数:13
相关论文
共 50 条
  • [1] HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin
    Abbate, I
    Lo Iacono, O
    Di Stefano, R
    Cappiello, G
    Girardi, E
    Longo, R
    Ferraro, D
    Antonucci, G
    Di Marco, V
    Solmone, M
    Craxì, A
    Ippolito, G
    Capobianchi, MR
    [J]. JOURNAL OF HEPATOLOGY, 2004, 40 (05) : 831 - 836
  • [2] Abbate I, 2003, J BIOL REG HOMEOS AG, V17, P162
  • [3] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
    Alter, MJ
    Kruszon-Moran, D
    Nainan, OV
    McQuillan, GM
    Gao, FX
    Moyer, LA
    Kaslow, RA
    Margolis, HS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) : 556 - 562
  • [4] Scope of worldwide hepatitis C problem
    Brown, RS
    Gaglio, PJ
    [J]. LIVER TRANSPLANTATION, 2003, 9 (11) : S10 - S13
  • [5] Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
    Chayama, K
    Tsubota, A
    Kobayashi, M
    Okamoto, K
    Hashimoto, M
    Miyano, Y
    Koike, H
    Kobayashi, M
    Koida, I
    Arase, Y
    Saitoh, S
    Suzuki, Y
    Murashima, N
    Ikeda, K
    Kumada, H
    [J]. HEPATOLOGY, 1997, 25 (03) : 745 - 749
  • [6] Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
    Enomoto, N
    Sakuma, I
    Asahina, Y
    Kurosaki, M
    Murakami, T
    Yamamoto, C
    Ogura, Y
    Izumi, N
    Marumo, F
    Sato, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) : 77 - 81
  • [7] Fan XF, 1999, AM J GASTROENTEROL, V94, P1347, DOI 10.1111/j.1572-0241.1999.01085.x
  • [8] The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
    Farci, P
    Shimoda, A
    Coiana, A
    Diaz, G
    Peddis, G
    Melpolder, JC
    Strazzera, A
    Chien, DY
    Munoz, SJ
    Balestrieri, A
    Purcell, RH
    Alter, HJ
    [J]. SCIENCE, 2000, 288 (5464) : 339 - 344
  • [9] Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
    Farci, P
    Strazzera, R
    Alter, HJ
    Farci, S
    Degioannis, D
    Coiana, A
    Peddis, G
    Usai, F
    Serra, G
    Chessa, L
    Diaz, G
    Balestrieri, A
    Purcell, RH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) : 3081 - 3086
  • [10] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982